Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MR Clear all
Recruiting Phase 2 Interventional

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT07734038
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib
Procedure · Drug
Lead sponsor
Kerry Rogers
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational

Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis

NCT03055455
View directory record Official record
Conditions
Septic Shock
Interventions
MR imaging
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 24, 2026, 10:22 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Neurofeedback With Real-Time fMRI for Treatment of PTSD

NCT03243149
View directory record Official record
Conditions
PTSD
Interventions
fMRI - GE Medical System
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting No phase listed Observational

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

NCT03127709
View directory record Official record
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Not yet recruiting Phase 2 Interventional

Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

NCT07634601
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Interventions
Biospecimen Collection, Computed Tomography, Elacestrant, Everolimus, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

NCT05625594
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Aspiration, Biospecimen Collection, Catheterization, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Suspended Phase 3 Interventional

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

NCT06568172
View directory record Official record
Conditions
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
196
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT04190446
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

NCT06385483
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting No phase listed Observational

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)

NCT06911099
View directory record Official record
Conditions
Atrial Functional Mitral Regurgitation, Mitral Insufficiency
Interventions
Not listed
Lead sponsor
University Hospital of Cologne
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2035
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
579
States / cities
Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

NCT06238648
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer

NCT00032058
View directory record Official record
Conditions
Prostate Cancer
Interventions
magnetic resonance imaging, magnetic resonance spectroscopic imaging
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
San Francisco, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls

NCT02572648
View directory record Official record
Conditions
Heart Failure
Interventions
Brain Imaging (Neuroimaging), Cognitive Function Assessment
Other
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 24, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Virtual Neuro-Navigation System for Personalized Community Based TMS

NCT04956081
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Neuro-navigated Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Woodbridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

NCT05954559
View directory record Official record
Conditions
Myocardial Fibrosis
Interventions
Elucirem (Gadopiclenol)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

NCT04166318
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
659
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Not listed No phase listed Observational

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

NCT01341132
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
MRI Scan of the Liver enhanced with Eovist
Procedure
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 24, 2026, 10:22 PM EDT
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

NCT07050186
View directory record Official record
Conditions
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Digital Photography, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Completed No phase listed Observational

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

NCT02978586
View directory record Official record
Conditions
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
[Ga-68]PSMA PET/MR
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

NCT07544992
View directory record Official record
Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

NCT07673341
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Tafasitamab, Venetoclax
Procedure · Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 24, 2026, 10:22 PM EDT